CervoMed Inc.

$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for CervoMed Inc.

DatePrice TargetRatingAnalyst
12/17/2024Buy → Neutral
H.C. Wainwright
12/11/2024Buy → Neutral
Chardan Capital Markets
12/11/2024Overweight → Underweight
Morgan Stanley
12/10/2024Buy → Hold
D. Boral Capital
12/6/2024$45.00Buy
ROTH MKM
12/5/2024$42.00Buy
H.C. Wainwright
9/18/2024$55.00Buy
Chardan Capital Markets
7/26/2024$35.00Overweight
Morgan Stanley
2/15/2024$50.00Buy
Canaccord Genuity
See more ratings

CervoMed Inc. Press Releases

Fastest customizable press release news feed in the world

See more
  • CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

    — Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokinetic data obtained in a food-effect study in healthy volunteers in 4Q 2024 indicates that the new capsules achieved targeted mean plasma concentrations — — Within-subject comparison of certain participants who received older capsules during the double-blind phase of the RewinD-LB trial and new capsules in the open-label extension phase indicated that participants receiving newer batch capsules, on average, achieved targeted plasma concentration

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed to Present at the 8th International Lewy Body Dementia Conference

    BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in deme

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (the "Company"), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Company's common stock on the grant date, and each will vest in 36 equal installments on the last day of each month over a three-year period, subject to the employee's continued employment with the Co

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

    —Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial— —Trial participants continue to receive neflamapimod during open-label extension— BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) ("CervoMed" or the "Company"), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the tre

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

    Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB Phase 2b clinical trial in early-stage dementia with Lewy bodies (DLB) in December 2024 BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of frontotemporal dementia (FTD). "We are pleased to have received

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Key Senior Leadership Appointments

    BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medical Officer at two biotech companies and has significant expertise with both early and late-stage drug development. She previously led clinical development programs in cystic fibrosis and multiple sclerosis at Vertex and Biogen, respectively. Additionally, Mark De Rosch, Ph.D., FRAPS, recently jo

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

    The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the advances made by the company towards developing the first treatment for Dementia with Lewy bodies (DLB) BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced today it was awarded by the Galien Foundation the Prix Galien USA 2024 prize in the Best Startup category. Cervomed was selected as one of two recipients from a total of 43 nominees in the Best Start

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed to Participate in Upcoming Investor Conferences

    BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentation Date: Tuesday, November 19, 2024Time: 3:00 PM ETWebcast Link: click here The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

    Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB Neflamapimod treatment previously led to significant reduction in plasma GFAP levels (p=0.015 versus placebo) and these reductions were associated with an improvement in clinical outcomes The RewinD-LB Phase 2b clinical study successfully enrolled a DLB patient population that is optimized to show the treatment effect of neflamapimod when topline data are reported in December BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on d

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

    • On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced the Last Patient Last Visit in RewinD-LB, a Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB). CervoMed remains on track to report

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

CervoMed Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

CervoMed Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

CervoMed Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

CervoMed Inc. SEC Filings

See more

CervoMed Inc. Leadership Updates

Live Leadership Updates

See more
  • CervoMed to Appoint William Elder as Chief Financial Officer

    BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

    - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

    Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp

    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

CervoMed Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more